The Production and Characterisation of Monoclonal Antibodies Against Human Prolactin and the Development of a Two-Site Immunoradiometric Assay

Abstract

Monoclonal antibodies against human prolactin (PRL) have been produced and characterised and used to develop a sensitive two-site immunoradiometric assay (IRMA). Nine anti-PRL monoclonal antibodies were assessed for reactivity in immunoblotting experiments with PRL, hPL, hGH and pituitary gland extract. There was no detectable crossreactivity with hPL or hGH. In liquid phase radioimmunoassay (RIA) studies using three of the antibodies there was no detectable crossreaction from hPL or hGH. Five antibodies were positive in immunocytochemical studies using sections of human pituitary gland. Using FPLC purified monoclonal antibodies, a two-site IRMA was developed that could assay PRL over the range 17.5-3500 mIU per litre and was readily adapted to assaying serum samples from patients. The two-site IRMA could be performed within one day without loss of sensitivity and has potential as a rapid and simple method for screening clinical samples.

Serum prolactin in coeliac disease: a marker for disease activity

“…Serum samples were collected and frozen at −70°C until analysis. The serum prolactin level was measured by immunoradiometric assay (Promed, Holland) 12. Normal concentrations of prolactin ranged from 5 to 20 μg/l and hyperprolactinaemia was defined at >20 μg/l.…”